Owkin is an AI biotechnology company dedicated to improving patient outcomes by utilizing artificial intelligence to identify optimal treatments tailored to individual needs. The company bridges the gap between complex biological research and the practical application of new diagnostics and therapeutic solutions, enhancing collaboration between biopharma entities and academic researchers. Owkin aims to expedite the delivery of innovative drugs and diagnostic tools to market, thereby transforming how healthcare is approached. With over $300 million raised in funding from prominent investors, including major biopharma firms, Owkin has rapidly evolved into a significant player in the life sciences sector. The organization values a collaborative work environment that encourages creativity, scientific rigor, and a commitment to advancing healthcare through cutting-edge technology.